JPMorgan Chase & Co. Sells 228,182 Shares of Vera Therapeutics, Inc. $VERA

JPMorgan Chase & Co. cut its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 73.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 82,365 shares of the company’s stock after selling 228,182 shares during the period. JPMorgan Chase & Co.’s holdings in Vera Therapeutics were worth $2,394,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Deerfield Management Company L.P. increased its holdings in shares of Vera Therapeutics by 8.8% in the 3rd quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company’s stock valued at $105,812,000 after acquiring an additional 293,040 shares during the period. Vanguard Group Inc. increased its holdings in shares of Vera Therapeutics by 6.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,190,653 shares of the company’s stock valued at $92,720,000 after acquiring an additional 189,545 shares during the period. Vestal Point Capital LP increased its holdings in shares of Vera Therapeutics by 24.0% in the 2nd quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock valued at $73,036,000 after acquiring an additional 600,000 shares during the period. Integral Health Asset Management LLC increased its holdings in shares of Vera Therapeutics by 47.8% in the 3rd quarter. Integral Health Asset Management LLC now owns 1,700,000 shares of the company’s stock valued at $49,402,000 after acquiring an additional 550,000 shares during the period. Finally, Schroder Investment Management Group increased its holdings in shares of Vera Therapeutics by 82.4% in the 3rd quarter. Schroder Investment Management Group now owns 679,992 shares of the company’s stock valued at $19,652,000 after acquiring an additional 307,243 shares during the period. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on VERA shares. JPMorgan Chase & Co. cut their price target on Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating on the stock in a report on Friday, December 19th. Bank of America lifted their price target on Vera Therapeutics from $48.00 to $66.00 and gave the company a “buy” rating in a report on Friday, December 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a report on Wednesday, January 21st. Evercore lifted their price target on Vera Therapeutics from $75.00 to $97.00 and gave the company an “outperform” rating in a report on Monday, December 8th. Finally, The Goldman Sachs Group boosted their target price on Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Vera Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $81.45.

Vera Therapeutics Stock Performance

Shares of VERA opened at $40.44 on Tuesday. The stock has a 50-day moving average of $41.50 and a two-hundred day moving average of $38.79. Vera Therapeutics, Inc. has a one year low of $18.53 and a one year high of $56.05. The company has a debt-to-equity ratio of 0.12, a quick ratio of 13.64 and a current ratio of 13.64. The stock has a market cap of $2.89 billion, a P/E ratio of -8.68 and a beta of 1.17.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.05). During the same period in the prior year, the business earned ($0.72) earnings per share. As a group, research analysts predict that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Insider Activity at Vera Therapeutics

In other Vera Therapeutics news, COO David Lee Johnson sold 2,579 shares of Vera Therapeutics stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $108,266.42. Following the completion of the sale, the chief operating officer owned 45,727 shares of the company’s stock, valued at approximately $1,919,619.46. The trade was a 5.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Marshall Fordyce sold 16,925 shares of Vera Therapeutics stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $710,511.50. Following the sale, the chief executive officer directly owned 257,163 shares of the company’s stock, valued at approximately $10,795,702.74. This represents a 6.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 33,490 shares of company stock worth $1,405,910 in the last quarter. 16.30% of the stock is owned by insiders.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.